Cost–effectiveness of apixaban and warfarin in the prevention of thromboembolic complications among atrial fibrillation patients
Crossref DOI link:
Update policy: https://doi.org/10.1007/SPRINGER_CROSSMARK_POLICY
Soini, Erkki J.
Saarni, Samuli I.
Funding for this research was provided by:
Oy Bristol-Myers Squibb (Finland) Ab
unspecified valid from 2016-08-17